G6423
吉西他滨
≥98% (HPLC), powder, deoxycytidine analog
别名:
2′;-脱氧-2′,2′-二氟胞苷; dFDC, Gemzar (Lilly), LY-188011, dFdC, dFdCyd
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C9H11F2N3O4 · HCl
化学文摘社编号:
分子量:
299.66
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
产品名称
吉西他滨, ≥98% (HPLC)
质量水平
方案
≥98% (HPLC)
表单
powder
储存条件
desiccated
protect from light
溶解性
H2O: ≥10 mg/mL
创始人
Eli Lilly
储存温度
room temp
SMILES字符串
Cl.NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F
InChI
1S/C9H11F2N3O4.ClH/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17;/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17);1H/t4-,6-,7-;/m1./s1
InChI key
OKKDEIYWILRZIA-OSZBKLCCSA-N
基因信息
正在寻找类似产品? 访问 产品对比指南
一般描述
Gemcitabineis a pyrimidine nucleoside analog of deoxycytidine. It exhibits anticancereffects against various cancers.
应用
Gemcitabinehydrochloride has been used as a chemotherapeutic agent to study its effects onthe human pancreatic adenocarcinoma cell lineIt has been used as a chemotherapeutic to study its resistance inpancreatic stellate cells (PSCs)It has also been used to study its effects on patient-derivedxenograft (PDX) organoids.
生化/生理作用
吉西他滨是一种广泛使用的抗肿瘤药和抗代谢药。
吉西他滨是诊所和研究实验室中广泛使用的抗肿瘤药物。它是一种抗肿瘤药和抗代谢药。
特点和优势
This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
警示用语：
Danger
危险声明
危险分类
Repr. 1B
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
此项目有
Yuan Chi et al.
Frontiers in oncology, 11, 671082-671082 (2021-12-07)
Pancreatic cancer is associated with poor prognosis and dismal survival rates. This study aims to investigate roles of lncRNA UCA1-loaded exosomes secreted by pancreatic stellate cells (PSCs) in Gemcitabine (Gem) resistance of pancreatic cancer under hypoxia, which involves the methylation
Abdullah Shopit et al.
Phytomedicine : international journal of phytotherapy and phytopharmacology, 91, 153711-153711 (2021-08-28)
Gemcitabine (GCB) is a first-line chemotherapeutic drug for pancreatic cancer (PCa). However, the resistance begins developing within weeks of chemotherapy. SPINK1 overexpression enhances resistance to chemotherapy. In a recent study, our laboratory established that the oleanolic acid (OA) derivative, K73-03
M Barton-Burke
Cancer nursing, 22(2), 176-183 (1999-04-27)
There have been exciting new developments in anticancer therapy over the past few years. One such therapy uses gemcitabine (GemzarR), an antimetabolite approved in 1996 by the Food and Drug Administration (FDA) for first-line treatment of locally advanced (nonresectable stage
Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors.
Isabel Romero-Calvo et al.
Molecular cancer research : MCR, 17(1), 70-83 (2018-09-02)
Patient-derived pancreatic ductal adenocarcinoma (PDAC) organoid systems show great promise for understanding the biological underpinnings of disease and advancing therapeutic precision medicine. Despite the increased use of organoids, the fidelity of molecular features, genetic heterogeneity, and drug response to the
Nikki K Lytle et al.
Cell, 177(3), 572-586 (2019-04-09)
Drug resistance and relapse remain key challenges in pancreatic cancer. Here, we have used RNA sequencing (RNA-seq), chromatin immunoprecipitation (ChIP)-seq, and genome-wide CRISPR analysis to map the molecular dependencies of pancreatic cancer stem cells, highly therapy-resistant cells that preferentially drive tumorigenesis
商品
Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.
Apoptosis regulation involves multiple pathways and molecules for cellular homeostasis.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持